Novo Nordisk (NVO) GLP-1 Drug Regarded Safe for Brain by Oxford

Novo Nordisk (NVO) was once again in the news on Jul 12 after the University of Oxford announced results from an exploratory one-year study of semaglutide, a GLP-1 receptor agonist, showing that the drug was not associated with a risk of adverse neuropsychiatric outcomes compared with other antidiabetic medications. On the contrary, treatment with semaglutide was associated with benefits like lowering the risk of cognitive problems and nicotine misuse. This opens the scope for further evaluation of the drug ...